Innate Pharma announces partial clinical hold on lacutamab IND placed by FDA

Innate Pharma announced that the FDA has placed a partial clinical hold on the lacutamab IND leading to a pause in new patient enrollment to the company’s ongoing lacutamab trials IPH4102-201 and 102. The partial clinical hold follows one fatal case of hemophagocytic lymphohistiocytosis, or HLH, a rare hematologic disorder. Enrollment is also completed to the initial cohort of the Phase 1b PTCL trial and is awaiting a futility interim analysis to progress to the next stage. Innate Pharma is on track for final data from the Phase 2 TELLOMAK trial and preliminary data on PTCL in Q4.